---
title: "ASMB.US (ASMB.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ASMB.US/news.md"
symbol: "ASMB.US"
name: "ASMB.US"
parent: "https://longbridge.com/en/quote/ASMB.US.md"
datetime: "2026-05-21T17:32:51.316Z"
locales:
  - [en](https://longbridge.com/en/quote/ASMB.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ASMB.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ASMB.US/news.md)
---

# ASMB.US (ASMB.US) — Related News

### [Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference](https://longbridge.com/en/news/286404799.md)
*2026-05-14T11:05:48.000Z*
> Assembly Biosciences (NASDAQ: ASMB) Chief Medical Officer Anuj Gaggar presented the company's virology strategy at a Ban

### [Analyst Reiterates Buy on Assembly Biosciences, Maintains $50 Price Target Amid Pipeline Progress and 2028 Cash Runway](https://longbridge.com/en/news/286291566.md)
*2026-05-13T16:06:04.000Z*
> H.C. Wainwright analyst Patrick Trucchio has reiterated a Buy rating on Assembly Biosciences, maintaining a price target

### [Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026 | ASMB Stock News](https://longbridge.com/en/news/286205540.md)
*2026-05-12T22:00:00.000Z*
> Assembly Biosciences, Inc. (Nasdaq: ASMB) announced it will present topline Phase 1a data on its investigational oral he

### [Assembly Biosciences GAAP EPS of -$0.54 beats by $0.03, revenue of $8.21M beats by $1.26M](https://longbridge.com/en/news/285623777.md)
*2026-05-07T21:27:21.000Z*
> Assembly Biosciences GAAP EPS of -$0.54 beats by $0.03, revenue of $8.21M beats by $1.26M

### [Assembly Biosciences | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 8.213 M](https://longbridge.com/en/news/285611162.md)
*2026-05-07T20:22:21.000Z*
### [Marvel Biosciences Announces Closing of Convertible Debenture Offering | MBCOF Stock News](https://longbridge.com/en/news/283193684.md)
*2026-04-17T12:30:00.000Z*
> Marvel Biosciences Corp. has completed a non-brokered private placement of unsecured convertible debentures, raising $50

### [Marvel Biosciences Wins Non-Dilutive Backing for MB-204 Phase I Trial](https://longbridge.com/en/news/281907259.md)
*2026-04-07T15:52:56.000Z*
> Marvel Biosciences Wins Non-Dilutive Backing for MB-204 Phase I Trial

### [Assembly Biosciences (ASMB) Gets a Buy from Guggenheim](https://longbridge.com/en/news/281778844.md)
*2026-04-06T16:05:19.000Z*
> Guggenheim's Vamil Divan has reiterated a Buy rating on Assembly Biosciences (ASMB) with a price target of $43.00. Divan